Internal Medicine, Medical Oncology · Los Angeles, CA
NPI
1306834338
Since 2005
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
10001 Venice Blvd Apt 402
Los Angeles, CA, 90034
Phone (808) 445-4085
Groups this clinician bills Medicare through
Medicare paid, 2024
$80K
7,611 services
Medicare patients, 2024
52
Average age 69
Drug cost, 2024
$1.5M
383 prescriptions
Company payments, 2025
$2,913
From 32 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael P Castro was code 85025 (blood count), 126 times for 45 patients. In total Michael P Castro billed 7,611 services in 59 codes, and Medicare paid $80K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-12-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 85025 Blood Count | Office | 126 | 45 | $7.61 | $959 |
| 80053 Clinical Chemistry | Office | 115 | 45 | $10.35 | $1,190 |
| 99214 Office E&M - Established | Office | 108 | 38 | $106.00 | $11K |
| 83615 Clinical Chemistry | Office | 85 | 38 | $5.92 | $503 |
| 84100 Clinical Chemistry | Office | 82 | 39 | $4.65 | $381 |
| 36415 Venipuncture Blood Collection | Office | 79 | 39 | $8.65 | $683 |
| 83735 Clinical Chemistry | Office | 58 | 31 | $6.57 | $381 |
| 99215 Office E&M - Established | Office | 57 | 26 | $152.12 | $8,671 |
| 83540 Clinical Chemistry | Office | 39 | 30 | $6.34 | $247 |
| 82728 Clinical Chemistry | Office | 39 | 30 | $13.36 | $521 |
| 82378 Clinical Chemistry | Office | 37 | 19 | $18.58 | $687 |
| 84443 Clinical Chemistry | Office | 35 | 25 | $16.46 | $576 |
| 84439 Clinical Chemistry | Office | 35 | 25 | $8.84 | $309 |
| 82607 Clinical Chemistry | Office | 22 | 20 | $14.78 | $325 |
| 84550 Clinical Chemistry | Office | 19 | 16 | $4.43 | $84.17 |
By year: 2022 $84K for 9,742 services; 2023 $291K for 22,289 services; 2024 $80K for 7,611 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 126 | 45 | $7.61 | $959 |
| 80053 Clinical Chemistry | 115 | 45 | $10.35 | $1,190 |
| 83615 Clinical Chemistry | 85 | 38 | $5.92 | $503 |
| 84100 Clinical Chemistry | 82 | 39 | $4.65 | $381 |
| 36415 Venipuncture Blood Collection | 79 | 39 | $8.65 | $683 |
| 83735 Clinical Chemistry | 58 | 31 | $6.57 | $381 |
| 83540 Clinical Chemistry | 39 | 30 | $6.34 | $247 |
| 82728 Clinical Chemistry | 39 | 30 | $13.36 | $521 |
| 82378 Clinical Chemistry | 37 | 19 | $18.58 | $687 |
| 84439 Clinical Chemistry | 35 | 25 | $8.84 | $309 |
Medicare prescription drug claims, 2024
In 2024, the drug Michael P Castro prescribed most often to Medicare patients was Famotidine, with 34 prescriptions and refills. In total Michael P Castro wrote 383 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Famotidine Generic | 34 | 48 | Under 11 | $282 |
| Jakafi Ruxolitinib Phosphate | 24 | 24 | Under 11 | $240K |
| Xtandi Enzalutamide | 22 | 22 | Under 11 | $260K |
| Truqap Capivasertib | 18 | 19 | Under 11 | $408K |
| Losartan Potassium Generic | 17 | 38 | Under 11 | $75.84 |
| Atorvastatin Calcium Generic | 15 | 39 | Under 11 | $125 |
| Leucovorin Calcium Generic | 14 | 14 | Under 11 | $1,556 |
| Levetiracetam Generic | 14 | 14 | Under 11 | $145 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 12 | 12 | Under 11 | $238 |
| Fentanyl Generic | 11 | 11 | Under 11 | $1,571 |
| Olanzapine Generic | 11 | 11 | Under 11 | $42.29 |
| Tazverik Tazemetostat Hydrobromide | 11 | 11 | Under 11 | $221K |
Brand drugs: - claims; generic drugs: 262 claims; opioid claims: 29.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael P Castro $2,913 ($2,913 in general payments such as food, travel and fees) from 32 companies. The largest payer was Intuitive Surgical, Inc. with $895.
| Company | Payments | Amount |
|---|---|---|
| Intuitive Surgical, Inc. ISRG | 6 | $895 |
| AstraZeneca Pharmaceuticals LP AZN | 9 | $248 |
| SpringWorks Therapeutics, Inc. | 5 | $197 |
| Pfizer Inc. PFE | 7 | $182 |
| Janssen Biotech, Inc. JNJ | 6 | $144 |
| Stemline Therapeutics Inc. | 3 | $112 |
| Abbvie Inc. ABBV | 4 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 3 | $85.68 |
| Tempus AI, Inc TEM | 1 | $70.31 |
| Genmab U.S., Inc. GMAB | 2 | $68.92 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.